MammaPrint™ 70-gene signature: Another milestone in personalized medical care for breast cancer patients

Expert Review of Molecular Diagnostics

Volumn 9, Issue 5, 2009, Pages 417-422

  Slodkowska, Elzbieta A ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

70 gene profile; 70 gene signature; Breast cancer; Gene expression profiling; MammaPrint

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RNA; TAMOXIFEN;

ANGIOGENESIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PATIENT; DEVICE; DIAGNOSTIC PROCEDURE; HISTOPATHOLOGY; HUMAN; MEDICAL CARE; METASTASIS; MICROARRAY ANALYSIS; PROGNOSIS; REVIEW; STANDARD; TECHNOLOGY; UNITED STATES; VALIDATION PROCESS; ADULT; BREAST TUMOR; CLINICAL TRIAL; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONCOLOGY; RISK;

ADULT; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RISK;

EID: 67650410053     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.32     Document Type: Review

References (30)

1. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobágyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13, 477-493 (2008). •• Comprehensive review of currently available multigene assays. (Pubitemid 351872866)
2. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res. 11, 205 (2009).
3. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
4. Ross JS, Linette GP, Stec J et al. Breast cancer biomarkers and molecular medicine. Expert Rev. Mol. Diagn. 3, 573-585 (2003). (Pubitemid 37101873)
5. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98, 262-272 (2006). (Pubitemid 43264710)
6. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000). (Pubitemid 30671230)
7. Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin. Oncol. 34, S10-S16 (2007). (Pubitemid 46778751)
8. Stec J, Wang J, Coombes K et al. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J. Mol. Diagn. 7, 357-367 (2005). (Pubitemid 41149651)
9. Gruvberger-Saal SK, Cunliffe HE, Carr KM et al. Microarrays in breast cancer research and clinical practice - the future lies ahead. Endocr. Relat. Cancer 13, 1017-1031 (2006). (Pubitemid 46212561)
10. Ross JS, Symmans WF, Pusztai L et al. Breast cancer biomarkers. Adv. Clin. Chem. 40, 99-125 (2005).
11. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002). • Signature and assay development.
12. Buyse M, Loi S, van 't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst 98, 1183-1192 (2006). (Pubitemid 44390989)
13. van de Vijver MJ, He YD, van 't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
14. Bueno-de-Mesquita JM, Keijzer R, Linn SC et al. A new independent validation of the 70-gene signature in node-negative breast cancer. Eur. J. Cancer 4, 131 (2006). •• External validation of 70-gene signature.
15. Bueno-de-Mesquita JM, van Hartren WH, Retel VP et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 8, 1079-1087 (2007). (Pubitemid 350182954)
16. Wittner BS, Sgroi DC, Ryan PD et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin. Cancer Res. 14, 2988-2993 (2008).
17. Mook S, Schmidt MK, Viale G et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. DOI: 10.1007/s10549-008- 0130-132 (2008) (Epub ahead of print).
18. Cardoso F, van 't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26, 729-735 (2008). •• Outline of Microarray In Node Negative Disease May Avoid Chemotherapy Trial (MINDACT) study.
19. Mook S, Van't veer LJ, Rutgers E et al. Individualization of therapy using MammaPrint: From development to the MINDACT trial. Cancer Genomics Proteomics 4, 147-155 (2007). (Pubitemid 46807341)
20. Bogaerts J, Cardoso F, Buyse M et al. Prospective evaluation of a gene signature as a new prognostic tool in early stage breast cancer: background and challenges in the design of MINDACT (Microarray In Node Negative Disease May Avoid Chemotherapy Trial). Nat. Clin. Pract. Oncol. 3, 540-551 (2006).
21. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726-3734 (2006). (Pubitemid 46622311)
22. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004). (Pubitemid 40051905)
23. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol. 4, 603-610 (2008).
24. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2007).
25. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109, 1011-1018 (2007). (Pubitemid 46435378)
26. Mook S, Bonnefoi H, Pruneri G et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur. J. Cancer 45, 1201-1208 (2009).
27. Ioannidis JP. Is molecular profiling ready for use in clinical decision making? Oncologist 12, 301-311 (2007). (Pubitemid 46556796)
28. Jenssen TK, Hovig E. Gene-expression profiling in breast cancer. Lancet 365, 634-635 (2005).
29. www.fda.gov/cdrh/oivd/guidance/1610.pdf
30. Agendia www.agendia.com